Die Verfahren sollten einer der folgenden OECD-Leitlinien sowie sonstigen einschlägigen OECD-Leitlinien für In-vitro- und In-vivo-Tests entsprechen: 471 (Salmonella
typhimurium Reverse Mutation Test), 472 (Escherichia coli Reverse Mutation
Test), 473 (In vitro Mammalian Chromosome Aberration
Test), 474 (Mammalian Erythrocyte Micronucleus
Test), 475 (Mammalian Bone Marrow Chromosome Aberration
Test), 476 (In vitro Mammalian Cell
Gene Mutat ...[+++]ion Test) oder 482 (Genetic Toxicology: DNA Damage and Repair, Unscheduled DNA Synthesis in Mammalian Cells in vitro).De protocollen moeten in overeenstemming zijn met OESO-richtsnoer 471 (Salmonella
typhimurium Reverse Mutation Test), 472 (Escherichia coli Reverse Mutation
Test), 473 (in vitro Mammalian Chromosomal Aberration
Test), 474 (Mammalian Erythrocyte Micronucleus
Test), 475 (Mammalian Bone Marrow Chromosomal Aberration
Test), 476 (in vitro Mammalian Cell Gene Mutation Test) of 482 (Unscheduled DNA Synthesis in Mammalian Cel
ls in vitr ...[+++]o) en met andere relevante OESO-richtsnoeren voor in-vitro- en in-vivotests.